Lactacystin, a proteasome inhibitor, enhances BMP-induced osteoblastic differentiation by increasing active Smads

Yuki Ito, Hidefumi Fukushima, Takenobu Katagiri, Yoshinori Seo, Shizu Hirata, Min Zhang, Ryuji Hosokawa, Eijiro Jimi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Proteasome inhibitors enhance bone formation and osteoblastic differentiation in vivo and in vitro. In the present study, we examined whether the molecular mechanisms of lactacystin, one of many proteasome inhibitors, stimulated the osteoblastic differentiation of C2C12 cells that is induced by bone morphogenetic proteins (BMPs). Pretreatment with lactacystin enhanced the alkaline phosphatase (ALP) activity induced by BMP2, BMP4 or BMP7, but lactacystin did not induce ALP in the absence of BMPs. In addition, lactacystin-stimulated BMP2 induced mRNA expression of ALP, type I collagen, osteonectin, osteocalcin, Id1, Osterix, and Runx2. Lactacystin maintained BMP2-induced phosphorylation of Smad1/5/8 and increased the length of time that these Smads were bound to target DNA. Moreover, lactacystin prevented BMP receptor-induced Smad degradation. This enhancement of BMP2-induced ALP activity and Smad phosphorylation by lactacystin was also observed in primary osteoblasts. These findings suggest that pretreatment with lactacystin accelerates BMP-induced osteoblastic differentiation by increasing the levels of phosphorylated Smads, which are maintained because BMP receptor-induced degradation is inhibited. We propose that optimized stimulation by proteasome inhibitors in a clinical setting may facilitate autogenous or BMP-induced bone formation in areas of defective bone.

Original languageEnglish
Pages (from-to)225-229
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume407
Issue number1
DOIs
Publication statusPublished - Apr 1 2011
Externally publishedYes

Fingerprint

Bone Morphogenetic Proteins
Proteasome Inhibitors
Alkaline Phosphatase
Bone Morphogenetic Protein Receptors
Bone
Phosphorylation
Osteogenesis
Osteonectin
Degradation
lactacystin
Osteocalcin
Osteoblasts
Collagen Type I
Cell Differentiation
Bone and Bones
Messenger RNA
DNA

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Lactacystin, a proteasome inhibitor, enhances BMP-induced osteoblastic differentiation by increasing active Smads. / Ito, Yuki; Fukushima, Hidefumi; Katagiri, Takenobu; Seo, Yoshinori; Hirata, Shizu; Zhang, Min; Hosokawa, Ryuji; Jimi, Eijiro.

In: Biochemical and Biophysical Research Communications, Vol. 407, No. 1, 01.04.2011, p. 225-229.

Research output: Contribution to journalArticle

Ito, Yuki ; Fukushima, Hidefumi ; Katagiri, Takenobu ; Seo, Yoshinori ; Hirata, Shizu ; Zhang, Min ; Hosokawa, Ryuji ; Jimi, Eijiro. / Lactacystin, a proteasome inhibitor, enhances BMP-induced osteoblastic differentiation by increasing active Smads. In: Biochemical and Biophysical Research Communications. 2011 ; Vol. 407, No. 1. pp. 225-229.
@article{9c96e153ed8749b6a7b187252c23f979,
title = "Lactacystin, a proteasome inhibitor, enhances BMP-induced osteoblastic differentiation by increasing active Smads",
abstract = "Proteasome inhibitors enhance bone formation and osteoblastic differentiation in vivo and in vitro. In the present study, we examined whether the molecular mechanisms of lactacystin, one of many proteasome inhibitors, stimulated the osteoblastic differentiation of C2C12 cells that is induced by bone morphogenetic proteins (BMPs). Pretreatment with lactacystin enhanced the alkaline phosphatase (ALP) activity induced by BMP2, BMP4 or BMP7, but lactacystin did not induce ALP in the absence of BMPs. In addition, lactacystin-stimulated BMP2 induced mRNA expression of ALP, type I collagen, osteonectin, osteocalcin, Id1, Osterix, and Runx2. Lactacystin maintained BMP2-induced phosphorylation of Smad1/5/8 and increased the length of time that these Smads were bound to target DNA. Moreover, lactacystin prevented BMP receptor-induced Smad degradation. This enhancement of BMP2-induced ALP activity and Smad phosphorylation by lactacystin was also observed in primary osteoblasts. These findings suggest that pretreatment with lactacystin accelerates BMP-induced osteoblastic differentiation by increasing the levels of phosphorylated Smads, which are maintained because BMP receptor-induced degradation is inhibited. We propose that optimized stimulation by proteasome inhibitors in a clinical setting may facilitate autogenous or BMP-induced bone formation in areas of defective bone.",
author = "Yuki Ito and Hidefumi Fukushima and Takenobu Katagiri and Yoshinori Seo and Shizu Hirata and Min Zhang and Ryuji Hosokawa and Eijiro Jimi",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.bbrc.2011.03.003",
language = "English",
volume = "407",
pages = "225--229",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Lactacystin, a proteasome inhibitor, enhances BMP-induced osteoblastic differentiation by increasing active Smads

AU - Ito, Yuki

AU - Fukushima, Hidefumi

AU - Katagiri, Takenobu

AU - Seo, Yoshinori

AU - Hirata, Shizu

AU - Zhang, Min

AU - Hosokawa, Ryuji

AU - Jimi, Eijiro

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Proteasome inhibitors enhance bone formation and osteoblastic differentiation in vivo and in vitro. In the present study, we examined whether the molecular mechanisms of lactacystin, one of many proteasome inhibitors, stimulated the osteoblastic differentiation of C2C12 cells that is induced by bone morphogenetic proteins (BMPs). Pretreatment with lactacystin enhanced the alkaline phosphatase (ALP) activity induced by BMP2, BMP4 or BMP7, but lactacystin did not induce ALP in the absence of BMPs. In addition, lactacystin-stimulated BMP2 induced mRNA expression of ALP, type I collagen, osteonectin, osteocalcin, Id1, Osterix, and Runx2. Lactacystin maintained BMP2-induced phosphorylation of Smad1/5/8 and increased the length of time that these Smads were bound to target DNA. Moreover, lactacystin prevented BMP receptor-induced Smad degradation. This enhancement of BMP2-induced ALP activity and Smad phosphorylation by lactacystin was also observed in primary osteoblasts. These findings suggest that pretreatment with lactacystin accelerates BMP-induced osteoblastic differentiation by increasing the levels of phosphorylated Smads, which are maintained because BMP receptor-induced degradation is inhibited. We propose that optimized stimulation by proteasome inhibitors in a clinical setting may facilitate autogenous or BMP-induced bone formation in areas of defective bone.

AB - Proteasome inhibitors enhance bone formation and osteoblastic differentiation in vivo and in vitro. In the present study, we examined whether the molecular mechanisms of lactacystin, one of many proteasome inhibitors, stimulated the osteoblastic differentiation of C2C12 cells that is induced by bone morphogenetic proteins (BMPs). Pretreatment with lactacystin enhanced the alkaline phosphatase (ALP) activity induced by BMP2, BMP4 or BMP7, but lactacystin did not induce ALP in the absence of BMPs. In addition, lactacystin-stimulated BMP2 induced mRNA expression of ALP, type I collagen, osteonectin, osteocalcin, Id1, Osterix, and Runx2. Lactacystin maintained BMP2-induced phosphorylation of Smad1/5/8 and increased the length of time that these Smads were bound to target DNA. Moreover, lactacystin prevented BMP receptor-induced Smad degradation. This enhancement of BMP2-induced ALP activity and Smad phosphorylation by lactacystin was also observed in primary osteoblasts. These findings suggest that pretreatment with lactacystin accelerates BMP-induced osteoblastic differentiation by increasing the levels of phosphorylated Smads, which are maintained because BMP receptor-induced degradation is inhibited. We propose that optimized stimulation by proteasome inhibitors in a clinical setting may facilitate autogenous or BMP-induced bone formation in areas of defective bone.

UR - http://www.scopus.com/inward/record.url?scp=79953163437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953163437&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2011.03.003

DO - 10.1016/j.bbrc.2011.03.003

M3 - Article

VL - 407

SP - 225

EP - 229

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -